Polypeptide for preventing or treating myocardial ischemia-reperfusion injury and application thereof
The lncRNA MSTRG 66788.1 encodes polypeptide 66788.1-aa through exercise-induced lncRNA MSTRG 66788.1-aa, which solves the treatment problem of myocardial ischemia and reperfusion injury, effectively inhibits ferrodynamic death of myocardial cells, improves myocardial function, replaces exercise therapy, and achieves dose-dependent therapeutic effects.
Patent Information
- Application Number
- CN202411262455.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-04-28
- Filing Date
- 2024-09-10
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-09-10
AI Technical Summary
Myocardial ischemia and reperfusion injury occurs during revascularization of acute myocardial infarction, and reperfusion therapy itself may cause additional damage. The existing treatment effect is limited, and there is a risk of exercise therapy. Drug alternatives are needed to improve myocardial ischemia. Reperfusion injury.
Exercise-induced lncRNA MSTRG 66788.1 was obtained through high-throughput screening, and the polypeptide 66788.1-aa was verified to inhibit ferrodystrophy of cardiomyocytes, improve myocardial ischemia and reperfusion injury, replace exercise therapy, and provide a polypeptide and its drug application to prevent Or treat myocardial ischemia and reperfusion injury.
Polypeptide 66788.1-aa effectively inhibits ferrodystrophy of cardiomyocytes, improves myocardial ischemia and reperfusion injury, and the heart function in mice is significantly improved, and the effect is dose-dependent, reducing myocardial fibrosis and reducing myocardial injury area.
Smart Images

Figure CN119080908A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to a polypeptide for preventing or treating myocardial ischemia-reperfusion injury and its application. Background Art
[0002] Myocardial ischemia-reperfusion injury (MIR) mainly occurs during the revascularization process of acute myocardial infarction. Although reperfusion therapy is crucial for saving myocardial cells in the ischemic area after myocardial infarction, paradoxically, reperfusion itself can also cause additional damage. Sometimes the severity of myocardial ischemia-reperfusion injury is even no less severe than the damage caused by ischemia. The clinical treatment effects of most current response plans are still limited. There is evidence that appropriate exercise can improve myocardial ischemia-reperfusion injury after revascularization in patients with acute myocardial infarction and significantly improve patient prognosis. However, exercise therapy is not without risks. Excessive exercise may cause cardiac overload, increased heart rate, increased blood pressure, and a sharp increase in cardiac load and myocardial oxygen consumption, thereby inducing more severe myocardial ischemia. Therefore, replacing appropriate exercise with precise drug therapy will become an effective means to improve myocardial ischemia-reperfusion injury after revascularization in patients with myocardial infarction.
[0003] Myocardial cell death is the direct cause of myocardial ischemia-reperfusion injury, which ultimately leads to impaired cardiac function. Ferroptosis is a cell death mode that has been redefined in recent years, characterized by the accumulation of lipid peroxides and the imbalance of the oxidative antioxidant system. Many studies have confirmed that myocardial ischemia-reperfusion injury can induce myocardial cell ferroptosis. Although ferroptosis has been a hot topic in the field of myocardial ischemia-reperfusion injury research in recent years, its mechanism of occurrence still needs further exploration. The development of new ferroptosis inhibitory drugs targeting myocardial cells is considered to be an effective way to improve myocardial ischemia-reperfusion injury in the short term. It is worth noting that exercise can reduce the accumulation of ROS and lipid peroxidation by regulating iron metabolism and enhancing antioxidant defense, suggesting that ferroptosis may be a potential mechanism of action for exercise to improve myocardial ischemia-reperfusion injury.
[0004] Studies have shown that long noncoding RNA (lncRNA) contains small open reading frames (smORFs), which can encode polypeptides (smORF encoded polypeptides, SEPs). As endogenous polypeptides, SEPs have low toxicity, high specificity, good biocompatibility, and the potential to treat a variety of diseases. Given the huge size of lncRNA, it is suggested that a large number of SEPs are yet to be discovered. Currently, research on SEPs involved in tumor regulation and as tumor screening markers is in full swing. However, research on SEPs in myocardial ischemic diseases is still blank. Summary of the invention
[0005] The purpose of the present invention is to provide a polypeptide (66788.1-aa) for preventing or treating myocardial ischemia-reperfusion injury and its application.
[0006] In order to achieve the above object, the present invention adopts the following technical solutions:
[0007] 1. Eight-week-old adult male C57BL / 6J mice were randomly divided into a control group (sitting) and an experimental group (running). The mice in the experimental group ran at a speed of 12 m / min for 1 h / d for 8 weeks.
[0008] 2. lncRNA transcriptome sequencing was performed on the myocardial tissues of the two groups of mice to identify running-induced differential lncRNAs. The coding potential of these differential lncRNAs was evaluated using online tools such as NCBIORF and CPAT, and the target lncRNA MSTRG 66788.1 was identified based on the coding ability score and ORF length.
[0009] 3. The coding ability of the embedded smORF of the target lncRNA MSTRG 66788.1 was verified by constructing a fusion expression vector. After the cells were transfected with the fusion expression vector of smORF and enhanced green fluorescent protein (eGFP), the expression of the fusion protein was observed by the eGFP fluorescence signal; at the same time, the cells were collected, the fusion protein was detected by the eGFP antibody, and then the expression of the fusion protein was analyzed according to the molecular weight. LncRNA MSTRG 66788.1 can indeed encode a polypeptide, and the polypeptide it encodes is named 66788.1-aa.
[0010] 4. Based on the lncRNA smORF sequence, 66788.1-aa was synthesized in vitro. The polypeptide sequence is MRWPLEKRNWCRYVLVSTEEIKTSHPKVCVLTGSSPMYFLLGLKPGANG.
[0011] Based on the above technical solution, the first aspect of the present invention provides a polypeptide, whose amino acid sequence is shown in SEQ ID No. 1:
[0012] MRWPLEKRNWCRYVLVSTEEIKTSHPKVCVLTGSSPMYFLLGLKPGAN G (SEQ ID No. 1).
[0013] Furthermore, the nucleotide sequence of the polypeptide encoding gene is shown in SEQ ID No.2:
[0014] Nucleotide sequence encoding polypeptide (ORF sequence encoding polypeptide above Lnc RNA MSTRG 66788.1):
[0015] ATGCGATGGCCTCTTGAGAAGAGGAATTGGTGTAGATACGTCTTGGTAAGCACTGAAGAAATAAAGACTTCTCACCCAAAGTGTGTGTCCTCACTGGCTCTTCTCCCATGTACTTCCTGTTAGGTCTCAAACCTGGGGCAAATGGTTAA (SEQ ID No. 2).
[0016] Lnc RNA MSTRG 66788.1 sequence encoding polypeptide (MSTRG.66788.1 73300448-3301594):
[0017] (SEQ ID No.3).
[0018] The second aspect of the present invention provides a use of the polypeptide as described above in the preparation of a drug for preventing or treating myocardial ischemia-reperfusion injury.
[0019] Furthermore, the polypeptide improves myocardial ischemia-reperfusion injury, and the effect is dose-dependent.
[0020] Furthermore, the polypeptide is used in the preparation of a drug that effectively reduces the degree of myocardial fibrosis and reduces the area of myocardial damage.
[0021] The third aspect of the present invention provides a drug for preventing or treating myocardial ischemia-reperfusion injury, wherein the active ingredient is the polypeptide as described above.
[0022] Furthermore, the medicine also includes a pharmaceutically acceptable carrier.
[0023] Furthermore, the pharmaceutically acceptable carrier is a pharmaceutically acceptable excipient, suspending agent, filler and / or diluent.
[0024] In a fourth aspect of the present invention, a modified polypeptide is provided, the amino acid sequence of which is shown in SEQ ID No.5:
[0025] MRWPLEKRNWCRYVLVSTEEIKTSHPKVCVLTGSSPMYFLLGLKPGANGWLSEAGPVVTVRALRGTGSW(SEQ ID No.5)
[0026] The fifth aspect of the present invention provides a use of the modified polypeptide as described above in the preparation of a drug for preventing or treating myocardial ischemia-reperfusion injury.
[0027] The present invention has the advantages that:
[0028] The present invention obtains an exercise-induced lncRNA MSTRG 66788.1 through high-throughput screening. Functional studies show that the SEPs 66788.1-aa encoded by it can effectively inhibit myocardial cell ferroptosis and improve the cardiac function of mice with myocardial ischemia-reperfusion injury, indicating that 66788.1-aa has the potential to replace exercise and become a specific drug for improving myocardial ischemia-reperfusion injury, eliminating the risks brought by excessive exercise. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 :24 hours after the establishment of IR / I model in mice, the levels of cTNT and CK-MB in peripheral blood were detected;
[0030] Labeling: (1) sham, sham operation control group; (2) IR / I, myocardial ischemia-reperfusion injury control group; (3) 66788.1-aa+IR / I, myocardial ischemia-reperfusion injury 66788.1-aa group (myocardial multi-point injection). N = 10:18:19 (cTNT figure). N = 3:15:10 (cTNT figure).
[0031] Figure 2 : TTC staining of frozen sections of the heart 24 days after mouse IR / I modeling;
[0032] Label explanation: (1) sham, sham operation group; (2) IR / I, myocardial ischemia-reperfusion injury group; (3) 66788.1-aa+IR / I, myocardial ischemia-reperfusion injury 66788.1-aa (4 μg / μl) group (myocardial multi-point injection). Infract area, infarct area = (infarct area of 5 heart sections) / (total area of 5 heart sections); N = 5:16:10; *P < 0.05.
[0033] Figure 3 :The results of echocardiography of mice IR / I model at 30 days;
[0034] Label description: (1) sham, sham operation group; (2) IR / I, myocardial ischemia-reperfusion group; (3) 66788.1-aa+IR / I, myocardial ischemia-reperfusion 66788.1-aa (4 μg / μl) group (myocardial multi-point injection). EF, left ventricular ejection fraction; FS, left ventricular fractional shortening; N=15:39:28; *P<0.05, **P<0.01, ***P<0.001, ****P<0.001.
[0035] Figure 4 : Masson staining results of paraffin sections of the heart of mice IR / I model 30 days later;
[0036] Note: (1) sham, sham operation group; (2) IR / I, myocardial ischemia-reperfusion injury group; (3)
[0037] 66788.1-aa+IR / I, myocardial ischemia-reperfusion injury 66788.1-aa (4 μg / μl) group (multiple injections into the myocardium); N=5.
[0038] Figure 5 :24 hours after the establishment of IR / I model in mice, the levels of cTNT and CK-MB in peripheral blood were detected;
[0039] Labeling: (1) sham, sham operation control group; (2) IR / I, myocardial ischemia-reperfusion injury control group; (3) 66788.1-aa (myocardial multipoint injection) + IR / I, myocardial ischemia-reperfusion injury 66788.1-aa group (myocardial multipoint injection); (4) 66788.1-aa (tai vein) + IRI, myocardial ischemia-reperfusion injury + 66788.1-aa-targeting group (tail vein injection); N = 10:18:19 (cTNT figure). N = 10:18:18:23. DETAILED DESCRIPTION
[0040] The specific implementation methods provided by the present invention are described in detail below in conjunction with examples.
[0041] Embodiment 1:
[0042] To simulate human myocardial ischemia-reperfusion injury, an experimental scheme was adopted to establish a myocardial ischemia-reperfusion model in the descending anterior artery (LAD) of C57BL / 6J mice. The proximal end of the LAD was ligated to induce left ventricular ischemia for 40 minutes, and then the ligation was untied to achieve LAD recanalization for 24 hours to establish a myocardial ischemia-reperfusion injury model (IR / I model).
[0043] In order to evaluate the effect of 66788.1-aa on the cardiac function of IR / I mice, the levels of myocardial injury markers cTnT and CK-MB in the peripheral blood of mice were detected 24 hours after modeling. Figure 1 ), compared with the sham group, the levels of cTnT and CK-MB in the peripheral blood of the IR / I group were significantly increased; compared with the IR / I group, the levels of cTnT and CK-MB in the peripheral blood of the 66788.1-aa+IR / I group showed a downward trend, and the downward trend became more obvious with the increase of 66788.1-aa concentration. This indicates that in the mouse IR / I model, 66788.1-aa can improve myocardial ischemia-reperfusion injury, and the effect is dose-dependent.
[0044] Embodiment 2:
[0045] To simulate human myocardial ischemia-reperfusion injury, an experimental protocol was adopted to establish a myocardial ischemia-reperfusion model in the descending anterior artery (LAD) of C57BL / 6J mice. Left ventricular ischemia was induced for 40 minutes by ligating the proximal end of the LAD, followed by untying the ligature and recanalizing the LAD for 24 hours to produce reperfusion injury.
[0046] In order to observe the damage of the heart more intuitively, the present invention performed triphenyltitanium tetrachloride (TTC) staining analysis on five sections of the heart to evaluate the size and range of the infarct area. Compared with the IR / I group, the myocardial infarction area in the 66788.1-aa (concentration of 4ug / μl) + IR / I group was significantly reduced ( Figure 2 ). This indicates that 66788.1-aa can effectively improve myocardial ischemia-reperfusion injury.
[0047] After 30 days of IR / I modeling, the present invention used cardiac ultrasound to evaluate changes in cardiac function. The results showed that ( Figure 3 ), compared with the IR / I group, the EF and FS in the 66788.1-aa (concentration of 4ug / μl) + IR / I group also showed an upward trend, indicating that timely revascularization after myocardial infarction combined with the treatment of 66788.1-aa can further save cardiac function.
[0048] The results of Masson staining at 30 days after modeling showed ( Figure 4 ), compared with the IR / I group, the area of collagen fibers in the hearts of mice in the 66788.1-aa (concentration of 4ug / μl) + IR / I group was significantly reduced, and the location was more concentrated, which indicates that 66788.1-aa can effectively reduce the degree of myocardial fibrosis and reduce the area of myocardial damage.
[0049] The above results indicate that 66788.1-aa can improve myocardial ischemia-reperfusion injury in mice.
[0050] The peptide sequence + myocardial targeting peptide sequence constitutes a new sequence:
[0051] Among them, the polypeptide sequence:
[0052] MRWPLEKRNWCRYVLVSTEEIKTSHPKVCVLTGSSPMYFLLGLKPGAN G(SEQ ID No.1)
[0053] Myocardial targeting peptide: WLSEAGPVVTVRALRGTGSW (SEQ ID No. 4)
[0054] Peptide + myocardial targeting peptide (66788.1-aa-targeting) sequence:
[0055] MRWPLEKRNWCRYVLVSTEEIKTSHPKVCVLTGSSPMYFLLGLKPGANGWLSEAGPVVTVRALRGTGSW(SEQ ID No.5)
[0056] Myocardial multi-point injection method of peptides:
[0057] The myocardial multipoint injection procedure is a method of injecting drugs or viruses directly into the heart tissue. The following are the main steps of the procedure:
[0058] 1. Preparation before the experiment: Anesthetize the mice and fix them on the operating table.
[0059] 2. Exposure and fixation of the heart: trim the chest hair, disinfect the surgical area, open the chest and expose the heart, and fix the position of the heart with sutures or instruments.
[0060] 3. Peptide injection: Select multiple injection points (usually 3-5 points) on the myocardial surface, and inject an appropriate amount of peptide (4μg / μl peptide solution, a total of 25ul) at each point. During injection, care should be taken to avoid blood return and ensure that the injection solution is evenly distributed.
[0061] 4. Animal resuscitation and subsequent treatment: After the injection, the chest cavity was closed and sutured. After the mouse woke up, the endotracheal tube was removed, artificial respiration was stopped, and subsequent observation and care were carried out.
[0062] Tail vein injection:
[0063] The mouse tail vein injection method mainly includes the following steps:
[0064] 1. Preparation and fixation: Prepare 1ml syringe, alcohol cotton ball, mouse fixer and other tools. Put the mouse into the fixator, making sure that the mouse cannot move freely but does not affect its breathing.
[0065] 2. Vascular dilation: Wipe the mouse's tail with an alcohol cotton ball, or soak it in warm water, heat it with an infrared lamp, etc. to dilate the blood vessels.
[0066] 3. Needle insertion and injection: Locate the mouse tail vein, usually the left and right tail veins for injection. The needle and the blood vessel are at an angle of about 30 degrees, with the needle tip bevel facing upwards. Gently pierce the skin and the needle is immediately parallel to the blood vessel at 45 degrees. After confirming that the needle is in the blood vessel, slowly push the drug solution
[0067] 4. Hemostasis and recovery: After the injection, press the injection site with medical cotton to stop bleeding. Take the mouse out of the fixator and put it back in the cage to recover.
[0068] Figure 5 The results showed that the tail vein administration of targeting peptide-modified peptides and multi-point myocardial administration of targeting peptides were equally effective.
[0069] The preferred embodiments of the present invention have been specifically described above, but the present invention is not limited to the embodiments. Those skilled in the art may make various equivalent modifications or substitutions without violating the spirit of the present invention. These equivalent modifications or substitutions are all included in the scope defined by the claims of this application.
Claims
1. A polypeptide, characterized in that Its amino acid sequence is shown in SEQ ID No.
1.
2. The polypeptide according to claim 1, characterized in that The nucleotide sequence of the polypeptide encoding gene is shown in SEQ ID No.
2.
3. Use of the polypeptide according to claim 1 in the preparation of a drug for preventing or treating myocardial ischemia-reperfusion injury.
4. Use of the polypeptide according to claim 3 in the preparation of a drug for preventing or treating myocardial ischemia-reperfusion injury, characterized in that: The polypeptide is used in the preparation of a drug that effectively reduces the degree of myocardial fibrosis and reduces the area of myocardial damage.
5. A drug for preventing or treating myocardial ischemia-reperfusion injury, characterized in that: The active ingredient is the polypeptide as claimed in claim 1.
6. The drug according to claim 5, characterized in that The medicine also includes a pharmaceutically acceptable carrier.
7. The drug according to claim 6, characterized in that The pharmaceutically acceptable carrier is a pharmaceutically acceptable excipient, suspending agent, filler and / or diluent.
8. A modified polypeptide, characterized in that: Its amino acid sequence is shown in SEQ ID No.
5.
9. Use of the modified polypeptide according to claim 8 in the preparation of a drug for preventing or treating myocardial ischemia-reperfusion injury.
Citation Information
Patent Citations
Molecular guide system peptides and uses thereof
CN111278847A
IncRNA and application of detection reagent and inhibitor thereof
CN114941027A
Inhibition of lncExACT1 to Treat Heart Disease
US20230287427A1
